Skip to content

Tenofovir alafenamide

Vemlidy (tenofovir alafenamide) is a small molecule pharmaceutical. Tenofovir alafenamide was first approved as Vemlidy on 2016-11-10. It is used to treat chronic hepatitis b in the USA. It has been approved in Europe to treat hepatitis b. Genvoya's patents are valid until 2032-08-15 (FDA).
Trade Name Vemlidy
Common Name Tenofovir alafenamide
Indication chronic hepatitis b, hepatitis b
Drug Class Antivirals
Tenofovir alafenamide
Get full access now